General Information of Drug (ID: DMVL1SN)

Drug Name
ISIS 222039 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMVL1SN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PT2385 DMCSN69 Recurrent glioblastoma 2A00.00 Phase 2 [2]
ARO-HIF2 DMV5PEK Renal cell carcinoma 2C90 Phase 1 [3]
ISIS 222041 DMS03TR Discovery agent N.A. Investigative [1]
ISIS 222035 DMQY2EA Discovery agent N.A. Investigative [1]
ISIS 222001 DMD7HA3 Discovery agent N.A. Investigative [1]
ISIS 222043 DM26M7E Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HIF2-alpha messenger RNA (EPAS1 mRNA) TTWPA54 EPAS1_HUMAN Not Available [1]

References

1 US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 National Cancer Institute Drug Dictionary (drug name ARO-HIF2).